

NEWS AND VIEWS

Unveiling quality of clinical trial in China: from concern to confirmation

Huiyao Huang¹ | Yiru Hou^{1,2} | Hong Fang¹ | Ling Xu³ | Yue Yu¹ |
Huifang Zhang³ | Jing Zhang⁴ | Yu Tang¹ | Gongtao Lan⁵ | Wenbao Zhang⁶ |
Ning Li¹ 

¹Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China

²School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, P. R. China

³Department of Quality Medicine, Boehringer Ingelheim (China) Investment Co Ltd, Shanghai, P. R. China

⁴Department of Clinical Development Quality, Pfizer Research and Development (China), Beijing, P. R. China

⁵Department of Drug Registration, National Medical Products Administration, Beijing, P. R. China

⁶Bureau of Medical Administration, National Health Commission, Beijing, P. R. China

Correspondence

Ning Li, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, 17 South Panjiayuan Lane, Chaoyang District, Beijing, 100021, P. R. China.

Email: ncctrails@cicams.ac.cn

Wenbao Zhang, Bureau of Medical Administration, National Health Commission, Beijing 100044, P. R. China.

Email: zhangwenbao@126.com

Gongtao Lan, Department of Drug Registration, National Medical Products Administration, Beijing, 100022, P. R. China.

Email: langongtao@126.com

Funding information

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Grant/Award Number: 2021-I2M-1-045; National Anti-Tumor Drug Surveillance System of National Cancer Center, Grant/Award Number: DSS-YSF-2023009; National Key Research and Development Program of China, Grant/Award Number: 2021YFE0192400

The cornerstone of scientifically valid and ethically sound clinical trials is in compliance with established global quality requirements. Although China has made significant progress over the past 20 years in terms of the clinical trial quantity [1], quality and participation in multiregional trials [2], there still remain concerns regarding the trial

quality, which could be associated with the self-inspection initiative in 2015 [3].

In fact, the clinical trial quality in China has improved significantly during the past decade, which is reflected in the harmonized development trends of industry quality systems and regulatory quality promotion systems (Figure 1). In 2003, the China Good Clinical Practice (GCP) guidelines have been released, which identified the subject protection and data integrity as two basic principles of clinical trials. Four rigorous management policies started to implement in 2015, which required sponsors to re-evaluate the authenticity, integrity, and compliance of trial data before new drug application [4]. A series

List of abbreviations: EU, European Union; FDA, the US Food and Drug Administration; GCP, Good Clinical Practice; NAI, No Action Indicated; OAI, Official Action Indicated; QbD, Quality by Design; R&D, Research and Development; US, the United States; VAI, Voluntary Action Indicated.

Huiyao Huang, Yiru Hou, Hong Fang contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Authors. *Cancer Communications* published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.




FIGURE 1 Trends of the clinical trial quality system in China over the last two decades. CRO, Contract Research Organization; GCP, Good Clinical Practice; ICH, The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; ICH E6R1, ICH Harmonised Tripartite Guideline Guideline For Good Clinical Practice; IRB, Institutional Review Board; NDA, New Drug Application.

of high-profile policies were subsequently announced by the National Medical Products Administration, to improve quality ecosystem [5]. The regulatory supervision of trial quality in China has been significantly strengthened since then. In the meantime, a vital shift occurred since the quality culture in the industry emerged, and the approaches and tools of quality management systems were launched through information exchange and training.

Another milestone of trial quality progress in China was that China officially joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and began to integrate into the international drug regulatory system. This alliance initiated a proactive and harmonized process with China pledging to gradually transform its pharmaceutical regulatory authorities, industry and institutions to implement the international coalition's technical standards and guidelines [6]. Universal quality standard GCP guidelines and ideas, such as quality by design (QbD) and risk-based inspection, could be implemented almost simultaneously in China. Gradually, trial quality culture has been embedded in the full life cycle of drug research and development (R&D) in China.

All four regions, including China, the European Union (EU), the United States (US) and Japan, have a common consensus and harmonized standards to ensure the partic-

ipants' safety, data integrity and GCP compliance, and all have established similar regulatory frameworks for quality compliance (Supplementary Table S1). For example, local and international GCP standards and principles should be established, then inspection processes and checklists with key points for investigational drugs should be employed. In terms of inspection objects, types, requirements and disclosure, we observed consistency in general and slight differences between China and other regions. The difference is driven by that China's inspector put more efforts on scrutinizing trial institutions and laboratories, and relatively less on sponsors compared with the other regions. Notably, China and Japan lag behind the EU and the US regarding the disclosure of inspection findings. This is mainly due to no available database to disclose verification results yet.

Based on the US Food and Drug Administration (FDA) public database, the inspection findings from all the above regions were analyzed [7]. Between January 1st, 2016 and July 20th, 2023, a total of 2,732 eligible inspections were identified, with the majority (93.0%) of inspections occurring in the US. According to the severity of the issues identified, the inspection findings were evaluated and classified as official action indicated (OAI), voluntary action indicated (VAI) and no action indicated (NAI).




FIGURE 2 Distribution of final actions after FDA inspections in different regions. FDA, U.S Food and Drug Administration; NAI, No Action Indicated; OAI, Official Action Indicated; VAI, Voluntary Action Indicated.




FIGURE 3 Comparison of FDA inspection results for clinical trials conducted in China from 2009 to 2015 and 2016 to 2023. FDA, U.S Food and Drug Administration; NAI, No Action Indicated; OAI, Official Action Indicated; VAI, Voluntary Action Indicated.

Over past 7 years, the proportion of NAIs in the US was 71.3%, which was relatively lower than those in Japan (95.8%, $P = 0.008$) and Europe (79.7%, $P = 0.027$) (Figure 2). In addition, 35 (1.4%) inspections were classified as OAIs in the US, and inspection details of 31 inspections can be pinpointed. The main reasons for those OAIs were incomplete study records (100.0%), poor protocol compliance (87.1%), and non-compliant or inadequate informed consent (80.6%) (Supplementary Table S2). No significant differences in NAI proportion were noted between China and Japan ($P = 0.316$), the EU ($P = 0.768$), and the US ($P = 0.178$) (Figure 2). The possible reason for the lowest proportion of NAIs observed in the US might be the potential selection bias of included inspections. The inspections

included in other three regions were multiregional trials only, while those included in the US covered all registered trials. Therefore, the conclusion should be interpreted with caution considering potential bias, as the data generated were solely from the US FDA to ensure unity.

Between January 1st, 2009 and July 20th, 2023, 45 US FDA inspections on trials conducted in China were carried out. The proportion of NAIs has increased from 48.0% (2009-2015) to 85.0% (2016-2023) ($P = 0.018$) (Figure 3), demonstrating a significant improvement in trial quality in China.

The established trial quality ecosystem would benefit China in the long term and accelerate China's full integration into the global pharmaceutical R&D competition.

Meanwhile, we should also be aware that China is still facing some quality challenges.

First of all, China has yet to establish a transparent system to disclose inspection results [8]. Disclosure of verification results can help the industry focus on the main problems, proactively conduct risk management and closely collaborate with regulators to improve the overall trial quality. The annual reports of aggregated inspection findings have been publicly available, and the transparent inspection databases with trial-level information are highly expected.

Additionally, there are some emerging institutions in China that lack sufficient experience and sound quality management systems. Regulations and measures have been taken by both Chinese health authority and emerging institutions to improve their quality systems [9].

Finally, the quality challenges driven by decentralized trials and the application of new technologies are worth noticing. Similar to the rest of the world, China needs to implement the rule of QbD to fully transform the quality of clinical studies from reactive to proactive management. Modernized regulations should be developed and adopted. Regulatory inspection should focus more on critical quality aspects of trial conducting and reporting, instead of on verifying the accuracy of each datum.

AUTHOR CONTRIBUTIONS

Huiyao Huang, Yiru Hou, and Hong Fang contributed to framework planning and draft writing, as well as information collection, quality control, analysis and interpretation. Ning Li, Wenbao Zhang, and Gongtao Lan led the overall framework planning and data interpretation. Ling Xu, Yue Yu, Huifang Zhang, Jing Zhang, and Yu Tang participated in information collection, quality control, and data interpretation. All the authors reviewed and revised the manuscript.

ACKNOWLEDGEMENTS

The analysis and interpretation of the manuscript was supported by National Key Research and Development Program of China (2021YFE0192400), Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2021-I2M-1-045) and National Anti-Tumor Drug Surveillance System of National Cancer Center (DSS-YSF-2023009).

CONFLICT OF INTEREST STATEMENT

All authors disclose no competing interests.

DATA AVAILABILITY STATEMENT

Not applicable.

ETHICS STATEMENT

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

ORCID

Ning Li  <https://orcid.org/0000-0001-9162-0771>

REFERENCES

1. Li N, Huang HY, Wu DW, Yang ZM, Wang J, Wang JS, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. *Lancet Oncol*. 2019;20(11):e619-e626. [https://doi.org/10.1016/S1470-2045\(19\)30491-7](https://doi.org/10.1016/S1470-2045(19)30491-7)
2. Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, et al. Accelerating the integration of China into the global development of innovative anticancer drugs. *Lancet Oncol*. 2022;23(11):e515-e520. [https://doi.org/10.1016/S1470-2045\(22\)00483-1](https://doi.org/10.1016/S1470-2045(22)00483-1)
3. Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds. *BMJ*. 2016;355:i5396. <https://doi.org/10.1136/bmj.i5396>
4. Cyranoski D. China cracks down on fake data in drug trials. *Nature*. 2017;545(7654):275. <https://doi.org/10.1038/nature.2017.21977>
5. Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y, et al. Pharmacovigilance in China: Evolution and future challenges. *Br J Clin Pharmacol*. 2023;89(2):510-522. <https://doi.org/10.1111/bcp.15277>
6. National Medical Products Administration. Website of ICH work office [2023 08-20]. Available from: <https://www.cde.org.cn/ichWeb/index.jsp>
7. U.S Food and Drug Administration. Dashboards - Compliance Dashboards [2023 08-20]. Available from: <https://datadashboard.fda.gov/ora/cd/index.htm>
8. Ma Y, Wang Q, Duan Y, Shi Q, Zhang X, Yang K, et al. Promoting the quality and transparency of health research in China. *J Clin Epidemiol*. 2022;152:209-217. <https://doi.org/10.1016/j.jclinepi.2022.10.004>
9. Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. *Acta Pharm Sin B*. 2022;12(12):4365-4377. <https://doi.org/10.1016/j.apsb.2022.08.004>

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Huang H, Hou Y, Fang H, Xu L, Yu Y, Zhang H, et al. Unveiling quality of clinical trial in China: from concern to confirmation. *Cancer Commun*. 2024;44:576-579. <https://doi.org/10.1002/cac2.12528>